012790 — Sinil Pharmaceutical Co Share Price
Last trade - 00:00- KR₩70bn
- KR₩31bn
- KR₩81bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.46 | ||
| Price to Tang. Book | 0.47 | ||
| Price to Free Cashflow | 9.79 | ||
| Price to Sales | 0.87 | ||
| EV to EBITDA | 2.34 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.84% | ||
| Return on Equity | 5.04% | ||
| Operating Margin | 9.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 61,754.17 | 80,007.07 | 89,135.21 | 89,440.46 | 80,563.64 | n/a | n/a | 5.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -7.77 | +82.97 | +13.63 | +0.29 | -47.74 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sinil Pharmaceutical Co Ltd is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through five segments. The Pharmaceutical Business segment provides analgesics and anti-inflammatory drugs, hyperlipidemia treatments, skin disease treatments, folic acid deficiency treatments, as well as treatments for other diseases. The Cosmetics Business segment is engaged in the provision of skin care cosmetics. The Real Estate Business segment engages in the real estate rental business. The Health Functional Food Business segment provides vitamin supplements. The Quasi-Pharmaceutical Business segment provides yellow dust masks.
Directors
- Seong So Hong CHM (75)
- Jae Hyeon Hong CEO (47)
- Se Muk Choi OTH (51)
- Jeong Min Lee OTH (44)
- Jong Chang Park OTH (55)
- Hyeon Gi Hong DRC (38)
- Deok Bong Kim NID (67)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- December 16th, 1977
- Public Since
- August 13th, 1999
- No. of Shareholders
- 17,993
- No. of Employees
- 413
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 11,559,561
- Address
- 28, Boksanggol-gil, Angseong-myeon, CHUNGJU, 27304
- Web
- https://www.sinilpharm.com/
- Phone
- +82 437223300
- Auditors
- Ihnduck Accounting Corp.
Upcoming Events for 012790
Similar to 012790
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
AMINOLOGICS CO
Korea Exchange - KOSDAQ
FAQ
As of Today at 13:16 UTC, shares in Sinil Pharmaceutical Co are trading at KR₩6,040. This share price information is delayed by 15 minutes.
Shares in Sinil Pharmaceutical Co last closed at KR₩6,040 and the price had moved by -6.67% over the past 365 days. In terms of relative price strength the Sinil Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -38.62% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Sinil Pharmaceutical Co dividend yield is 3.15% based on the trailing twelve month period.
Last year, Sinil Pharmaceutical Co paid a total dividend of KR₩190, and it currently has a trailing dividend yield of 3.15%.Looking ahead, the next dividend pay date is 2026-04-30.
We do not have data on when Sinil Pharmaceutical Co is to next pay dividends. The historic dividend yield on Sinil Pharmaceutical Co shares is currently 3.15%.
To buy shares in Sinil Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩6,040, shares in Sinil Pharmaceutical Co had a market capitalisation of KR₩70bn.
Here are the trading details for Sinil Pharmaceutical Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 012790
Based on an overall assessment of its quality, value and momentum Sinil Pharmaceutical Co is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinil Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -21.62%.
As of the last closing price of KR₩6,040, shares in Sinil Pharmaceutical Co were trading -2.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sinil Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩6,040.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sinil Pharmaceutical Co's management team is headed by:
- Seong So Hong - CHM
- Jae Hyeon Hong - CEO
- Se Muk Choi - OTH
- Jeong Min Lee - OTH
- Jong Chang Park - OTH
- Hyeon Gi Hong - DRC
- Deok Bong Kim - NID